Mersana Therapeutics Inc. (NASDAQ:MRSN) finished Friday with a subtraction of -$0.02 to close at $1.21, a downside of -1.63 percent. An average of 2,011,200 shares of common stock have been traded in the last five days. There was a fall of -$0.0200 in the past week, and it reached a new high 9 times over the past 12 months. The last 20 days have seen an average of 3,187,450 shares traded, while the 50-day average volume stands at 8,896,811.
MRSN stock has increased by 13.08% in the last month. The company shares reached their 1-month lowest point of $0.8014 on 07/27/23. With the stock rallying to its 52-week high on 06/12/23, shares of the company touched a low of $0.80 and a high of $9.62 in 52 weeks. It has reached a new high 20 times so far this year and lost -79.35% or -$4.6500 in price. In spite of this, the price is down -87.42% from the 52-week high.
Insider Transactions
MRSN stock investors should be aware that Mersana Therapeutics Inc. (MRSN) stock had its last reported insider trading activity 9 days ago on Aug 17. In this transaction, the insider spent $2,251. SVP, Chief Legal Officer, Carvajal Alejandra, disposed of 3,944 shares at a price of $3.89 on Apr 27. The insider now owns more than $15,342 worth of shares. Prior to that, President & CEO Protopapas Anna went on to Sale 17,346 shares at $5.74 each on Jan 17. An amount of $99,566 was transacted.
Valuation Metrics
Mersana Therapeutics Inc. (MRSN) stock’s beta is 1.41. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 3.65, the price-to-book (PB) ratio at 1.55.
Financial Health
The quick ratio of Mersana Therapeutics Inc. for the three months ended June 29 was 4.00, and the current ratio was 4.00, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.28 and a total debt to equity ratio of 0.28 for the quarter ending June 29. Mersana Therapeutics Inc.’s EBITDA margin for the year ending June 29 is -763.10%. Its gross profit as reported stood at $230.35 million compared to revenue of $26.58 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Mersana Therapeutics Inc.’s return on assets was -68.50%.
Earnings Surprise
For the three-month period that ended June 29, Mersana Therapeutics Inc. had $25.08 million in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$54.31 million in the quarter, while revenues of -$56.16 million were grew 3.85%. The analyst consensus anticipated Mersana Therapeutics Inc.’s latest quarter earnings to come in at -$0.44 per share, but it turned out to be -$0.47, a -6.80% surprise. For the quarter, EBITDA amounted to -$57.96 million. Shareholders own equity worth $120.51 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Mersana Therapeutics Inc. (MRSN) price momentum. RSI 9-day as of the close on 25 August was 31.40%, suggesting the stock is Neutral, with historical volatility in this time frame at 45.64%.
As of today, MRSN’s price is $1.2180 -1.63% or -$0.0200 from its 5-day moving average. MRSN is currently trading -3.97% lower than its 20-day SMA and -71.53% lower than its 100-day SMA. However, the stock’s current price level is -87.33% below the SMA50 and -81.78% below the SMA200.
The stochastic %K and %D were 37.66% and 45.24%, respectively, and the average true range (ATR) was 0.1355. With the 14-day stochastic at 30.61% and the average true range at 0.1895, the RSI (14) stands at 29.38%. The stock has reached 0.0000 on the 9-day MACD Oscillator while the 14-day reading was at -0.0076.
Analyst Ratings
Robert W. Baird downgraded Mersana Therapeutics Inc. (NASDAQ: MRSN) to a a Neutral rating in its most recent analyst report. Previously, the stock was rated as an Outperform. The consensus rating for Mersana Therapeutics Inc. (MRSN) among analysts is Hold. According to current brokerage recommendations, 1 brokerage firm advise that investors sell MRSN, while 6 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 2 others rate it as a “buy”.
What is MRSN’s price target for the next 12 months?
Analysts predict a range of price targets between $1.00 and $4.00, with a median target of $1.50. Taking a look at these predictions, the average price target given by analysts for Mersana Therapeutics Inc. (MRSN) stock is $2.00.
